RARS1 and mucosulfatidosis: The screening of 785 FDA-approved drugs on MSD patient cells led Schlotawa and co-workers [61] to the identification of two agonists of retinoic acid receptors (RARs) and retinoid X receptors (RXRs)—respectively, tazarotene and bexarotene.